Publicaciones en colaboración con investigadores/as de Consiglio Nazionale delle Ricerche (14)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2021

  1. miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

    Leukemia, Vol. 35, Núm. 3, pp. 823-834

2020

  1. MiR-216a acts as a negative regulator of breast cancer by modulating stemness properties and tumor microenvironment

    International Journal of Molecular Sciences, Vol. 21, Núm. 7

  2. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

2018

  1. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

2017

  1. AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy

    Molecular Therapy, Vol. 25, Núm. 12, pp. 2727-2742

2015

  1. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014

    Journal of Translational Medicine, Vol. 13, Núm. 1

2014

  1. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

    Journal of Translational Medicine, Vol. 12, Núm. 1

  2. L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

    Experimental Neurology, Vol. 253, pp. 180-191

  3. L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus

    Neuropharmacology, Vol. 79, pp. 90-100

  4. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease

    Journal of Neuropathology and Experimental Neurology, Vol. 73, Núm. 5, pp. 414-424

2011

  1. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

    Pharmacology and Therapeutics, Vol. 132, Núm. 3, pp. 280-299

2008

  1. Aortic intramural haematoma and chronic anticoagulation: Role of transoesophageal echocardiography

    European Journal of Echocardiography, Vol. 9, Núm. 1, pp. 56-57